Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.
D001500:BCG Vaccine / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D011424:Propionibacterium / Q000276:immunology*; D011897:Random Allocation; D012008:Recurrence; D012878:Skin Neoplasms / Q000628:therapy*; D013997:Time Factors
D001500:BCG Vaccine; D001428:Bacterial Vaccines